Ameriprise’s Harvard Bioscience HBIO Stock Holding History

Ameriprise’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,219	Closed	-$95K	–	3861
2020 Q4	$95K	Sell	2,219 -81	-4%	-$3.02K	﹤0.01%	3692
2020 Q3	$69K	Sell	2,300 -100	-4%	-$3.36K	﹤0.01%	3666
2020 Q2	$74K	Buy	+2,400	New	+$64.7K	﹤0.01%	3603
2018 Q4	–	Sell	-7,259	Closed	-$381K	–	3701
2018 Q3	$381K	Sell	7,259 -25,299	-78%	-$1.42M	﹤0.01%	3379
2018 Q2	$1.74M	Sell	32,558 -575	-2%	-$29.5K	﹤0.01%	2786
2018 Q1	$1.66M	Buy	33,133 +3,660	+12%	+$164K	﹤0.01%	2759
2017 Q4	$973K	Hold	29,473	–	–	﹤0.01%	2982
2017 Q3	$1.1M	Hold	29,473	–	–	﹤0.01%	2915
2017 Q2	$752K	Buy	+29,473	New	+$729K	﹤0.01%	3073
2013 Q4	–	Sell	-210	Closed	-$8K	–	5260
2013 Q3	$8K	Hold	210	–	–	﹤0.01%	5030
2013 Q2	$8K	Buy	+210	New	+$8.04K	﹤0.01%	4926

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ameriprise's HBIO Position: Q1 2021 in Review

Ameriprise sold out of Harvard Bioscience (HBIO) in Q1 2021, closing a stake of 2,219 shares — an estimated $95K sold.

Ameriprise first reported a position in HBIO in Q2 2013 and held it in 11 quarters. The position peaked at $1.74M in Q2 2018. 87 funds tracked by Wall St. Rank hold HBIO as of Q1 2021.

Ameriprise reported no remaining Harvard Bioscience position as of Q1 2021 after selling out during the quarter.
Ameriprise sold 2,219 Harvard Bioscience shares in Q1 2021, an estimated $95K.
Ameriprise first reported a position in Harvard Bioscience in Q2 2013 and held it in 11 quarters.
Ameriprise's Harvard Bioscience position peaked at $1.74M in Q2 2018.
87 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2021.

Based on Ameriprise's 13F filing for Q1 2021, filed 17 May 2021.